stockrowPfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −7.98%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. (PFE) Return on equity
Pfizer Inc.'s return on equity over the twelve months to 30 September 2026 was 4.42%, down 4.4 percentage points from fiscal 2025 (8.87%). Over the past ten years it has ranged from 2.29% (fiscal 2023) to 36.2% (fiscal 2022); the current reading is higher than 18% of that period. That is below the Drug Manufacturers General industry median of 5.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 8.87% | (0.16) |
| FY2024 | 9.03% | 6.74 |
| FY2023 | 2.29% | (33.90) |
| FY2022 | 36.2% | 5.00 |
| FY2021 | 31.2% | 16.76 |
| FY2020 | 14.4% | (10.77) |
| FY2019 | 25.2% | 8.72 |
| FY2018 | 16.5% | (15.94) |
| FY2017 | 32.4% | 20.86 |
| FY2016 | 11.6% | 1.37 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 78.4% |
| NVO Novo Nordisk A/S compare | 60.8% |
| BMY Bristol Myers Squibb Company compare | 44.0% |
| GSK GSK PLC Sponsored ADR compare | 25.5% |
| NVS Novartis AG compare | 24.4% |
| AZN AstraZeneca PLC compare | 22.6% |
| PFE Pfizer Inc. | 4.42% |
| SNY Sanofi compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −22.5% |
| Drug Manufacturers General industry median | 5.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement